Heartflow (HTFL) concentration risks

The company's disclosed concentration profile is defined by a single, high-share product dependency. The Heartflow FFRCT Analysis represented 98% of total revenue, meaning the entire commercial base of the business rests on a single product line. This is the highest possible product concentration: there is effectively no revenue diversification disclosed, and any disruption to FFRCT Analysis adoption, reimbursement coverage, clinical acceptance, or competitive displacement would flow through to nearly all of revenues with no offsetting contributions from other products. The character of this exposure is mixed. On the structural side, the concentration reflects a company in the early commercial stage of deploying a single cleared medical technology — a normal condition for single-product MedTech companies. On the dependency side, the filing acknowledges the product-specific risk that reimbursement decisions by payors, regulatory developments, or clinical practice shifts could materially affect the business given the absence of revenue from any other product. There are no disclosed geographic, customer, or supplier concentrations to layer onto this picture. The concentration profile is dominated entirely by product composition, and the product-level risk is both the defining feature and the primary watch variable. An investor's assessment of this company's concentration risk should be anchored on how durable the clinical and reimbursement position of the FFRCT Analysis is, since 98% of revenue is co-extensive with that single franchise.

For the engine’s reasoning on HTFL’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.